Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | HTR2B | P41595 | 2/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4734695 | 0.79 | EIF4A3 (0.32) | LMNASLC6A2HTR2BTRPA1CHRM1 | |
| SCHEMBL24665465 | 0.77 | EIF4A3 (0.31) | LMNASLC6A2HTR2BTRPA1CHRM1 | |
| SCHEMBL29820111 | 0.77 | GABRA1 (0.32) | LMNASLC6A2HTR2BTRPA1CHRM1 | |
| SCHEMBL24664573 | 0.77 | GABRA1 (0.32) | LMNASLC6A2HTR2BTRPA1CHRM1 | |
| SCHEMBL2609322 | 0.76 | CCR1 (0.40) | CCR1RAB9ACCR5LMNASLC6A2 | |
| SCHEMBL84353 | 0.76 | NOS2 (0.37) | GABRA1GABRB1GABRG2GABRB3GABRA5 | |
| SCHEMBL23792998 | 0.76 | LMNA (0.36) | LMNAEIF4A3GABRA1GABRB1 | |
| SCHEMBL22485162 | 0.74 | CCR1 (0.39) | CCR1RAB9ACCR5LMNASLC6A2 | |
| SCHEMBL11213577 | 0.74 | CCR1 (0.39) | CCR1RAB9ACCR5LMNASLC6A2 | |
| SCHEMBL20375150 | 0.74 | TXNRD1 (0.36) | CYP1A2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059661-A1 | N-(BENZHYDRYL)CYCLOALKYLCARBOXAMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-08-24 | — | — | US | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230159445-A1 | STAT INHIBITORY COMPOUNDS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-05-25 | — | — | US | disclosed |
| US-20230150946-A1 | HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-05-18 | — | — | US | disclosed |
| US-20230137956-A1 | ALPHA SUBSTITUTED STAT INHIBITORS AND COMPOSITIONS THEREOF | OXFORD FINANCE LLC | 2023-05-04 | — | — | US | disclosed |
| US-11634425-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20160362427-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2016-12-15 | — | — | US | disclosed |
| US-9464088-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-10-11 | — | — | US | disclosed |
| US-20140275031-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION (US) | 2014-09-18 | — | — | US | disclosed |
| US-8765734-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE CORPORATION (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20110224190-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| US-20100286151-A1 | 1-OXA-3-Azaspiro[4,5]Decan--2-One Derivatives For The Treatment Of Eating Disorders | BENTLEY JONATHAN | 2010-11-11 | — | — | US | disclosed |
| US-20100286151-A1 | 1-OXA-3-Azaspiro[4,5]Decan--2-One Derivatives For The Treatment Of Eating Disorders | BENTLEY JONATHAN | 2010-11-11 | — | — | US | disclosed |
| US-20090042897-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090042897-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362427-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK2 | CCR1 2352/4885RAB9A 2869/4885CCR5 3229/4885 |
| US-20230150946-A1 | HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS | STAT5A, STAT5B, STAT3 | CCR1 3983/4885RAB9A 1737/4885CCR5 2164/4885 |
| US-20230159445-A1 | STAT INHIBITORY COMPOUNDS AND COMPOSITIONS | STAT5A, STAT5B, STAT3 | CCR1 4468/4885RAB9A 1578/4885CCR5 2482/4885 |
| US-20230137956-A1 | ALPHA SUBSTITUTED STAT INHIBITORS AND COMPOSITIONS THEREOF | STAT5A, STAT5B, STAT3 | CCR1 4272/4885RAB9A 1759/4885CCR5 2293/4885 |
| US-20140275031-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | CCR1 566/4885RAB9A 708/4885CCR5 959/4885 |
| US-20090042897-A1 | Chemical Compounds | NPY5R, NPY1R, NPY2R | CCR1 3609/4885RAB9A 1618/4885CCR5 2507/4885 |
| US-20110224190-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | CCR1 566/4885RAB9A 708/4885CCR5 959/4885 |
| US-11634425-B2 | Pharmaceutical compounds | GABRA6, CHRNA6, CNR1 | CCR1 146/4885RAB9A 1284/4885CCR5 214/4885 |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | CCR1 1029/4885RAB9A 2232/4885CCR5 915/4885 |
| US-20230265055-A1 | STAT INIHIBITORY COMPOUNDS AND COMPOSITIONS | STAT5B, STAT5A, STAT3 | CCR1 4385/4885RAB9A 1505/4885CCR5 2038/4885 |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | PAK2, PAK1, PAK6 | CCR1 3503/4885RAB9A 126/4885CCR5 3470/4885 |
| US-11827662-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | CCR1 3493/4885RAB9A 4028/4885CCR5 2608/4885 |
| US-20100286151-A1 | 1-OXA-3-Azaspiro[4,5]Decan--2-One Derivatives For The Treatment Of Eating Disorders | NPY5R, NPY1R, NPY4R | CCR1 369/4885RAB9A 3192/4885CCR5 501/4885 |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | CCR1 1029/4885RAB9A 2232/4885CCR5 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.